SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

NCT07549399 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Rectal Adenocarcinoma
High-Risk Cancer
MSS

Interventions

RADIATION: Short-Course Radiotherapy
DRUG: PD-1 monoclonal antibody
DRUG: mFOLFOX6 regimen
DRUG: Cetuximab
DRUG: Bevacizumab
PROCEDURE: Surgical resection

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University